Predictive Biosciences Forms Scientific Advisory Board

Back To Press & Events
Predictive Biosciences, an emerging venture developing diagnostic products for informed cancer management™, announced today the formation of a six member Scientific Advisory Board (SAB).


Scientists, clinicians to advise on development of urinary cancer biomarkers


Lexington, MA – May 30, 2007 – Predictive Biosciences, an emerging venture developing diagnostic products for informed cancer management™, announced today the formation of a six member Scientific Advisory Board (SAB). Predictive Biosciences is commercializing a portfolio of urinary protein biomarkers for precise, real-time cancer management, with a focus on cancer survivors. The company intends to develop patient-friendly, urine-based diagnostics across multiple epithelial cancers, initially in bladder cancer.


The Predictive Biosciences Scientific Advisory Board includes its Scientific Co-Founders: Dr. Marsha Moses, who also serves on the Board of Directors; and Dr. Bruce Zetter, who serves as Chairman of the Scientific Advisory Board. Dr. Marsha Moses is a Professor of Surgery at Harvard Medical School and Senior Principal Investigator in the Vascular Biology Program at Children's Hospital Boston. Dr. Bruce Zetter is the Chief Scientific Officer at Children's Hospital Boston and the Charles Nowiszewski Professor of Cancer Biology at Harvard Medical School.


Tony Shuber, Chief Technology Officer of Predictive Biosciences, remarks, “Establishment of our Scientific Advisory Board with world class scientists and physicians reinforces Predictive Biosciences’ position as a dynamic startup in oncology and diagnostics. The scientific and clinical expertise of these thought leaders will be invaluable to our development efforts as we commercialize our cancer diagnostic assays.”


Dr. John Reed states, “Currently, because of the lack of high-performing, noninvasive biomarkers, physicians rely on expensive and often invasive methods to monitor for recurrence in cancer survivors and to monitor therapeutic efficacy in cancer patients.” Added Dr. Reed, “I look forward to working with my colleagues on the Predictive Biosciences SAB as the company seeks to develop advanced diagnostic tools that address this unmet clinical need and to bring forth innovative products that enable patients and their physicians to truly personalize cancer survivor follow-up and treatment strategies.”


Profiles of New Predictive Biosciences SAB Members

 Dr. Martin Fleisher is Chair, Department of Clinical Laboratories and Chief, Clinical Chemistry Service at Memorial Sloan-Kettering Cancer Center. He is a widely known clinical chemist who is an expert in the areas of tumor markers, critical care laboratory medicine, laboratory automation and robotics, and specific protein analysis in B-cell dyscrasia. He is known for his contributions validating tumor markers and biomarkers for early detection of ovarian cancer and for monitoring how prostate cancer patients respond to treatment. He and his colleagues have also devised tests for estimating breast cancer risk and detecting metastases near the brain. Dr. Fleisher is the author of more than 130 publications and holds five US patents.


Dr. Judah Folkman is the Director of the Vascular Biology Program in the Department of Surgery at Children's Hospital Boston. He is the founder of the field of angiogenesis research, with the hypothesis that tumor growth is angiogenesisdependent. Dr. Folkman has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences. He has also received a Presidential appointment to the National Cancer Advisory Board of the National Institutes of Health. He holds honorary degrees from 17 universities and is the author of more than 400 original peer-reviewed papers and 109 book chapters and monographs.


Dr. Kevin Loughlin is Director of Urologic Research at Brigham and Women’s Hospital, a teaching hospital of Harvard Medical School. He has been actively involved in bladder cancer research and has lectured nationally and internationally on urologic research topics. Dr. Loughlin has a particular interest in bladder cancer markers to facilitate early detection and monitoring of bladder cancer. He has been selected for “Best Doctors in America” and “Top Doctors” by The Center for the Study of Services in Washington D.C. He has published more than 200 articles, abstracts, and letters in publications such as New England Journal of Medicine, Journal of Urology, and Laboratory Medicine.


Dr. John C. Reed is President and CEO of the Burnham Institute for Medical Research, a leading non-profit biomedical research institute. Dr. Reed is an active scientist, who has published more papers on the subject of programmed cell death than any other and whose scientific publications have received more citations than any other cell biologist worldwide for the past decade. Dr. Reed has co-founded three biotechnology companies and has been awarded over 50 patents. Dr. Reed currently serves on the editorial boards of over 12 scientific journals. He has also served as an advisor to the National Cancer Institute (NCI), American Cancer Society (ACS), and the American Association for Cancer Research (AACR).


About Predictive Biosciences

Predictive Biosciences is applying proprietary urinary protein biomarkers to develop and commercialize patient-friendly diagnostics across multiple cancer types. The company is initially focused on diagnostics for the precise, real-time management of cancer survivors. Predictive Biosciences is privately funded by Highland Capital Partners and IDG Ventures Boston and is based in Lexington, MA. For more information, visit Predictive Biosciences’ website at


Share On Twitter Linkedin